RealFeedApp Poster P055 details first-in-human study design for VY1706
Voyager Therapeutics announced poster presentations for investigational gene therapy VY1706 and monoclonal antibody VY7523 at the 19th CTAD conference in Boston, scheduled for November 2026.
- Field
- gene therapy
- What they did
- Voyager Therapeutics announced two poster presentations about gene therapy VY1706, which lowers tau protein production in the brain, and a monoclonal antibody VY7523 targeting the same protein.
- Why it matters
- The presentations show the design of the first-in-human study and baseline dosing characteristics, which may help develop treatments for Alzheimer's disease.
#tau pathology#gene therapy#monoclonal antibody#alzheimer's disease#voyager therapeutics
